Phase 2 Head and Neck Cancer Trial, Recruiting NCT05514275 Sponsor: Zhejiang Cancer Hospital Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT05514275
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of nasopharyngeal cancer (non-keratinizing type, confirmed by tissue biopsy according to World Health Organization classification)
  • People whose cancer has been staged as T3-4N1/N2-3, meaning the tumor is locally advanced with lymph node involvement (based on the 8th edition staging system)
  • People whose cancer has not spread to distant parts of the body
  • People who are in reasonably good general health, as measured by a standard performance scale (Karnofsky score above 70)
  • People whose blood counts are within acceptable ranges: white blood cell count, haemoglobin, and platelet levels all at or above specified minimum levels
  • People whose liver function tests are within acceptable limits, including specific enzymes (ALT, AST, ALP) and bilirubin levels
  • People whose kidneys are functioning well enough, with a creatinine clearance of at least 60 ml/min
  • People who have given written informed consent after being told about the investigational nature of the study
  • People whose tumor did not respond well (showed stable or worsening disease) after an initial course of chemotherapy given before the main treatment (called neoadjuvant chemotherapy)

Who may not be able to join:

  • People whose cancer is of a different tissue type — specifically the keratinizing squamous cell or basaloid squamous cell type
  • People whose treatment is planned with palliative (comfort-focused, non-curative) intent
  • People who have had another cancer in the past, except for certain treated skin cancers or cervical cancer that had not spread beyond the surface
  • People who are pregnant or breastfeeding
  • People who have previously received radiotherapy (except for certain non-melanoma skin cancers treated outside the planned radiation area)
  • People who have previously received chemotherapy or surgery (other than for diagnosis) to the primary tumor or nearby lymph nodes
  • People with serious ongoing health conditions that could increase risks or affect participation — for example, unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, or significant emotional or psychological difficulties
  • People whose tumor responded well (complete or partial response) to the initial course of chemotherapy given before the main treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ting Jin, MD, Department of Radiation Oncology, Zhejiang Cancer Hospital

Phone: +86-571-88128202

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
1 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Recurrence free survival (RFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov